Tuesday, July 1, 2014

Ranbaxy Set to Enter the U.S. Market with Valsartan, Diovan

The U.S. Food and Drug Administration (FDA) has granted approval to Ranbaxy Laboratories to launch the generic version of Diovan, blood pressure pill by Swiss drug maker Novartis AG. This long-awaited decision will make Ranbaxy the first rival drug maker to launch a copy of Diovan in the United States. FDA had earlier banned a number of Ranbaxy India facilities due to reports of poor production quality.

The total annual market sale of Diovan is estimated to be $2.19 billion. Its generic version, whose chemical name is Valsartan, will be manufactured and marketed in the U.S. market for the treatment of high blood pressure and heart failure. Ranbaxy is entitled to six-month exclusivity to sell it before other drugmakers become eligible to gain FDA approval and introduce their versions. Valsartan will be available in 40 mg, 80 mg, 160 mg, and 320 mg tablets.

According to BCC Research’s report, Global Markets for Generic Drugs, the global generics sector reached $269.8 billion in 2009. This is expected to reach $300.9 billion in 2013 and $ 518.5 billion in 2018, registering a compound annual growth rate (CAGR) of 11.5%.

Use this report for, but not limited to, the following reasons:
  • Gain an overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs, and drugs for respiratory conditions
  • Analyze global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
  • Examine strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, and also summarizing strategies employed by “originator” companies to forestall generic competition
  • Assess important trends by product categories and major country markets, acknowledging Brazil, China, India, Mexico, and Russia as among the rising markets for generic activity
To Order your copy of this report (or any of its chapters) or to download the Complimentary Introduction chapter, click here.

No comments:

Post a Comment

Bookmark and Share